← Leaderboards
Graham Johnson
Oricula Therapeutics, Llc
$1,116,263
Attributed
$2,232,526
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2014–17$2M$1.5M$1M$500K$0
'14
'15
'16
'17
Funding mix
By agency
NIH$2,232,526 · 2
By mechanism
R44$2,063,128 · 1
R43$169,398 · 1
Top collaborators
- Malcolm Gleser3 shared
Most similar at Oricula Therapeutics, Llc
Same institution · by research overlap
- Malcolm Gleser$1,116,263
Others in their field
Top investigators on “Hearing Impairment”
- Josef Coresh · New York University School Of Medicine$55,816,581
- Karen J Cruickshanks · University Of Wisconsin Madison$38,755,721
- Margaret A Palmer · University Of Maryland, College Park$28,563,002
- Katherine F Luzuriaga · Univ Of Massachusetts Med Sch Worcester$25,574,475
- Vicki A. Freedman · Madlyn/Leonard Abramson Ctr/Jewish Life$24,284,927
- Ulrich Mueller · Johns Hopkins University$23,500,443
Research focus
Hearing ImpairmentInfectionHair CellsHearing Impaired PersonsIncidenceFda ApprovedDosageDrug Use ScreeningHearingDoseGrantAerobicAntibioticsAffectBactericideAbdominal InfectionCystic Fibrosis PatientsCommunicable DiseasesCell DeathAminoglycoside AntibioticsChemotherapeutic AgentAdverse EffectsAminoglycosidesIntellectual Property
Grant awards (3)
Novel therapeutic agent to prevent hearing loss during aminoglycoside therapy$1,116,932
R44 · FY2017 · AI
Novel therapeutic agent to prevent hearing loss during aminoglycoside therapy$946,196
R44 · FY2016 · AI
New compounds to protect hearing during aminoglycoside therapy - safety study$169,398
R43 · FY2014 · DC